- Home
- Equipment
- asia middle east
- clinical study
Show results for
Refine by
Locations
- Asia & Middle East
- Afghanistan
- Armenia
- Azerbaijan
- Bahrain
- Bangladesh
- Bhutan
- Brunei Darussalam
- Cambodia
- China
- East Timor
- Georgia
- Guam
- Hong Kong
- India
- Indonesia
- Iran
- Iraq
- Israel
- Japan
- Jordan
- Kazakhstan
- Kuwait
- Kyrgyzstan
- Laos
- Lebanon
- Malaysia
- Maldives
- Mongolia
- Myanmar
- Nepal
- North Korea
- Oman
- Pakistan
- Palestinian Territories
- Philippines
- Qatar
- Russia
- Saudi Arabia
- Singapore
- South Korea
- Sri Lanka
- Syria
- Taiwan
- Tajikistan
- Thailand
- Turkmenistan
- United Arab Emirates
- Uzbekistan
- Vietnam
- Yemen
Clinical Study Equipment Supplied In Asia Middle East
116 equipment items found
Premium
Manufactured by:Environics, Inc. based inTolland, CONNECTICUT (USA)
The Environics® Series Reduced Oxygen Breathing Device 3 is the newest in our line of systems that simulate altitude exposure and can be utilized for both research and hypoxia familiariation training. The comparable S3000 model expands the ROBD3 functionality and is used when research or training needs to include hyperoxia and/or hypercapnia ...
Premium
Manufactured by:Environics, Inc. based inTolland, CONNECTICUT (USA)
The Environics Series Reduced Oxygen Breathing Device 2 is the next generation system that simulates altitude exposure and can be utilized for both research and hypoxia ...
Manufactured by:Boston Scientific based inMarlborough, MASSACHUSETTS (USA)
FARAFLEX is a large-area focal, deflectable catheter that has been shown to facilitate efficient, point-by-point ablation strategies in clinical studies.3 ...
Manufactured by:Boston Scientific based inMarlborough, MASSACHUSETTS (USA)
FARAPOINT is a precision focal ablation catheter designed from the ground up with only PFA in mind. In forthcoming clinical studies, FARAPOINT will aim to facilitate highly targeted therapy while leveraging the safety advantages of FARAPULSE PFA. ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX07, recombinant anti-epidermal growth factor receptor (EGFR) humanised monoclonal antibody injection independently researched and developed as biobetter. It was granted IND approvals to be evaluated in clinical trials in China and the United States. It demonstrated favorable safety and tolerability profile in a prospective, open-label, dose-escalation Phase 1 ...
Manufactured by:Alnylam Pharmaceuticals, Inc. based inCambridge, MASSACHUSETTS (USA)
AMVUTTRA™ (vutrisiran) is a prescription medicine given once every 3 months by a healthcare professional to treat the polyneuropathy caused by an illness called hereditary ATTR (hATTR) amyloidosis in adults. In an 18-month clinical study, AMVUTTRA-treated patients showed significant improvement in nerve function and quality of life at 9 months and ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
It is the first China-developed adalimumab biosimilar that is manufactured in a China and Europe GMP certificated manufacturing site, as well as the only adalimumab biosimilar evaluated in a Phase 3 clinical study among Chinese patients with plaque ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX04-O, recombinant anti-VEGF humanised monoclonal antibody injection. It is indicated for wet age-related macular degeneration (wAMD). HLX04-O was granted Phase 3 clinical study approvals in Australia, the United States, Singapore and the EU countries such as Latvia, Hungary and Spanish. In April 2022, the first patient in Australia and Latvia was dosed in the ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
On July 29, 2020, Vivozon applied for a patent for a second pipeline, VVZ-2471, and is currently conducting non-clinical toxicity studies. VVZ-2471 is a new drug candidate for treating chronic pain including neuropathic pain. Recently, the prevention and treatment potential of drug (morphine) addiction, anxiety, and depression have also been ...
by:OSSIO Inc based inWoburn, MASSACHUSETTS (USA)
Comprised of OSSIOfiber® Intelligent Bone Regeneration Technology, Fully integrates into native anatomy without adverse inflammation,, as proven in pre-clinical studies, Rivals performance of metal headless cannulated compression screws1, Can be trimmed to desired length ...
Manufactured by:Mesoblast Ltd. based inMelbourne, AUSTRALIA
MPC-25-IC is Mesoblast’s Phase 2 product candidate for the treatment of acute myocardial infarction. This is the first clinical study to evaluate an allogeneic cellular therapy delivered by intracoronary infusion in patients who have suffered an acute myocardial ...
Manufactured by:Xingtai Jiachuang Technology Co., Ltd. based inXingtai City, CHINA
This newly identified tracer of aging is directly involved in the synthesis of collagen fibers and consequently in the organization of the collagen thanks to its capacity to boost the synthesis of Lumican and Collagen I (in vitro tests), Dermican ensures that newly synthesized fibers are fully functional for a firmer and tighter skin (clinical study). Dedicated ...
by:Bened Biomedical Co., Ltd. based inTaipei, City, TAIWAN
Isolated from the human gut, Safe (GRAS pending, L. paracasei species EFSA QPS), Vegan, kosher and halal, Clinically studied for safety and effectiveness, VigorBiotics (PS23 strain postbiotics): shelf-stable, no need for refrigeration, resistant to harsh GI conditions, can be added to any food, beverage, or supplement ...
by:Bened Biomedical Co., Ltd. based inTaipei, City, TAIWAN
Lactiplantibacillus plantarum PS128: 12+ clinical studies. Probiotic Product of the Year Winner (2018 & 2021 NutraIngredients-Asia Awards). 60 million+ doses sold. Safe to use (GRAS, QPS). Vegan (isolated from mustard greens). Kosher and ...
Manufactured by:Kureha Corporation based inTokyo, JAPAN
These products exemplify Kureha's commitment to advancing medicinal chemistry and pharmaceutical innovations, which are strategically developed based on rigorous research and clinical studies. Kureha Corporation, known for its ethical approach, underscores that these medications should be prescribed by qualified healthcare professionals, ensuring that patients ...
Distributed by:American Laboratory Products Company (ALPCO) based inSalem, INDIA
We offer a range of research tools required to identify novel Cardiovascular Disease and Oxidative Health biomarkers, enabling scientists to test their relevance in basic, preclinical and clinical studies. Cardiovascular Disease (CVD) encompasses a constellation of diseases related to the heart and/or circulatory system. Two primary risk factors for CVD include ...
Manufactured by:BiomX based inNess Ziona, ISRAEL
We are developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections, a main contributor to morbidity and mortality in this disease. Phase 1b/2a clinical study in CF patients is composed of two parts. Results from Part 1 aimed to evaluate the safety, pharmacokinetics, and ...
Manufactured by:Medispec based inGaithersburg, MARYLAND (USA)
With more than a 1000 systems sold worldwide to the world’s leading medical institutions, the E3000 system offers the ideal combination between largest focal zone in the industry and bar pressure, resulting in superior results in clinical studies with high stone-free rate and extremely low re-treatment rate. The E3000 is a fully integrated mobile, modular ...
Manufactured by:Amoy Diagnostics Co., Ltd. based inXiamen, CHINA
25%, for BRAF1-4%, for NRAS is 1%, for HER2 2-4%, and for PIK3CA 1-3%. About 3-7% of NSCLC patients have gene fusion in ALK, 2% in ROS1, and 1% in RET. A large amount of clinical studies showed that gene mutation status is important efficacy predictor for targeted therapy. ...
Manufactured by:Amoy Diagnostics Co., Ltd. based inXiamen, CHINA
PIK3CA mutations in which lead to Activation of the PI3K pathway in breast cancer have been typically associated with resistance to endocrine therapy and poor prognosis. The clinical studies demonstrate that PI3K inhibitors has shown significantly high response rate in patients with PIK3CA-mutated breast ...